ArticleCureus2025
Glucagon-Like Peptide-1 (GLP-1) Agents and Cardiovascular Risk in Non-diabetic Patients: A Descriptive Analysis of National Health and Nutrition Examination Survey (NHANES), 2011-2018.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefit in patients with type 2 diabetes and, more recently, in obese adults without diabetes. However, real-world uptake of these agents during their early introduction remains unclear. The objective of this study was to describe the prevalence of GLP-1 RA use and provide baseline, pre-uptake, population-level estimates of major adverse cardiovascular events (MACE, including myocardial infarction, stroke, and cardiovascular death) and mortality among obese adults without diabetes, in the United States (US), using pooled National Health and Nutrition Examination Survey (NHANES) 2011-2018 data.
methodsWe analyzed adults aged ≥20 years with measured obesity (BMI ≥30 kg/m²) who did not meet criteria for diabetes in NHANES 2011-2018 (unweighted n = 6,065, representing a weighted US population of ≈69 million). Medication use was ascertained from the prescription drug questionnaire (medications taken in the prior 30 days). Baseline demographics, anthropometrics, and cardiometabolic risk factors are reported as survey-weighted estimates. Mortality (all-cause and cardiovascular) was ascertained via linkage to the 2019 National Death Index.
resultsAmong 6,065 obese, non-diabetic adults, none reported GLP-1 RA use in the 30 days preceding survey participation. The mean age was 45.9 years, and the mean body mass index was 35.7 kg/m². The cohort included 37,127,528 (53.6%) female and 44,259,809 (63.9%) non-Hispanic White participants. Hypertension was reported by 25,745,249 (37.2%), and 29,749,000 (42.9%) had smoked ≥100 cigarettes. Over follow-up, 2,661,169 (3.8%) of participants died from any cause, and 786,635 (1.1%) from cardiovascular causes. Because no GLP-1 RA users were identified, comparative (adjusted odds) analyses were not possible.
conclusionIn NHANES 2011-2018, GLP-1 RA use among obese US adults without diabetes was absent, reflecting minimal community uptake in this period. These survey-weighted estimates provide baseline, pre-uptake cardiovascular and mortality benchmarks and emphasize the need for analyses using more recent data to evaluate real-world GLP-1 adoption and outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.